



ASX ANNOUNCEMENT

25 JULY 2022

APPOINTMENT OF JASON B. LITTEN, M.D. TO CHIEF MEDICAL OFFICER

Cell therapy industry leader with substantial CAR T cell and NK cell drug development experience

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Dr Jason B. Litten, to the position of Chief Medical Officer (CMO). Dr Litten brings almost 15 years of leadership in drug development with the past five years dedicated to advancing NK and CAR T cell therapy clinical-stage programs in oncology.

Entering the cellular immunotherapy field in early days, Dr Litten has been part of the foundational clinical understanding of cell therapies, working on numerous CAR T and NK cell drug candidates. Most recently, Dr Litten served as the Chief Medical Officer at Artiva Biotherapeutics where he led the development of a portfolio of allogeneic Natural Killer (NK) cell therapies. Prior to Artiva, Dr Litten was Vice President Clinical Development at Juno Therapeutics where he built and oversaw the autologous solid tumour CAR T and TCRs cell therapy programs.

“I am truly delighted to welcome Jason to Chimeric as his deep experience and expertise in the development of autologous CAR T and allogeneic NK cell therapies in oncology will be invaluable to us as we continue to advance the development of our CAR T and NK cell therapies,” said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics.

“Chimeric is moving towards a major inflection point with the expansion of our CHM 0201 and 1101 clinical programs and the initiation of our CHM 2101 clinical program. Jason’s unique breadth and depth of cell therapy development experience will provide us with the clinical leadership necessary to advance our development rapidly and effectively.”

“I am very excited to join Chimeric at this important time in its growth,” said Dr Litten. “The potential for these innovative autologous CAR T cell and allogeneic NK cell therapy programs creates exciting opportunities to bring novel and potentially transformative therapies to cancer patients who need them.”

In addition to the key roles Dr Litten has held at cell therapy companies Artiva and Juno, Dr Litten was also previously a Vice President Clinical Development at Clovis Oncology and prior to that a Medical Director on the Oncology Clinical Development Team at Amgen.

For personal use only



Dr Litten earned his MD at Emory University, completed an internship and residency in General Pediatrics at the University of Miami and a fellowship in Pediatric Oncology at The University of Texas Southwestern.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in metastatic melanoma with future expansion to additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

For personal use only



CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

For personal use only